Needham Maintains Buy on Autolus Therapeutics, Raises Price Target to $11

Benzinga · 2d ago
Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $10 to $11.